CClinicalTrials.gg
Not yet recruitingNCT07786337Updated Aug 26, 2026

How Low Can You Go

An interventional study of Standard insufflation and Low insufflation in Pelvic Organ Prolapse, sponsored by University of Calgary. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a randomized controlled trial to determine if lower intraabdominal operating pressure reduces post-operative pain in patients scheduled to undergo laparoscopic uterosacral suspension surgery of the uterus or vaginal vault.

Read the detailed description

The primary objective of this research proposal is to answer the question: in patients scheduled to undergo laparoscopic uterosacral suspension surgery of the uterus or vaginal vault, does lower intraabdominal operating pressure reduce post-operative pain, measured using a standardized visual analogue scale?

Secondary outcomes include frequency of opioid and non-opioid analgesic prescriptions at time of discharge, rescue opioid analgesics in the day-surgery recovery unit, rate of unanticipated admission to hospital. Surgical safety outcomes will also be assessed including surgeon perception of operative field visibility, rate of surgeon requests to increase intraabdominal pressure, rate of conversion to open surgery, incidence of surgical complications (up to 30d post-operatively).

3.0 METHODS \& STATISTICAL ANALYSIS This study will be a double-blinded randomized controlled trial patients ≥18 years of age scheduled for laparoscopic uterosacral suspension surgery of either the uterus or vaginal vault at the Foothills Medical Centre, an academic tertiary hospital. Patients scheduled to receive concomitant prolapse, hysterectomy, or anti-incontinence surgeries will be included. Patients scheduled to receive concomitant non-urogynecologic surgery or those converted to an open, abdominal surgical approach will be excluded. For participants randomized to the lower IAP group, after entry into the abdominal-pelvic cavity, pneumoperitoneum pressure will be set and maintained at 10mmHg throughout the surgery. For those randomized to the normal IAP group, after entry into the abdominal-pelvic cavity, pneumoperitoneum pressure will be set and maintained at 15mmHg.

Data collected - including but not limited to:

  1. Preoperative data:

    a. Baseline demographics: age, BMI, past medical history

  2. Intraoperative Data:

    1. Duration of surgery, estimated blood loss, surgical complications
    2. Incidence of surgeon request for either: an increase in Trendelenburg positioning or increase in intraabdominal pressure settings
  3. Postoperative Data:

    1. Visual analogue pain scores (0-100mm) at 3 and 24 hours postoperatively
    2. Incidence of postoperative non-opioid and opioid prescriptions provided
    3. Incidence of unplanned hospital admission

The baseline characteristics of the primary cohort will be presented. Categorical data will be reported as counts and percentages and continuous data as means with standard deviations.

Continuous variables will be analyzed using a Student t-test for normally distributed data and Wilcoxon's rank sum test for nonparametric data. Frequencies and percentages will be calculated for categorical variables and compared using the Chi-squared or Fisher's exact test as appropriate. Statistical significance will be defined as p\<0.05.

Prior studies determined the minimum clinically significant difference in visual analogue pain scales scores to be 10mm, regardless of severity of pain. On the basis of this, a sample of 64 patients per group will be sought to achieve 80% power to detect an effect size of 0.5 (i.e. assuming a standard deviation of two points on the pain scale) using a two-group t-test with a two-sided significance level of 0.05. Accounting for a drop-out rate of 20%, a final sample size to 164 patients will be required.

02

Conditions studied

  • Pelvic Organ Prolapse

Browse trials for

Keywords

  • pelvic organ prolapse
  • laparoscopy
  • insufflation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • ≥18 years of age
  • planned laparoscopic uterosacral suspension surgery of the uterus or vaginal vault
  • patients with planned concomitant prolapse, hysterectomy, or anti-incontinence surgeries will be included

Exclusion criteria

Exclusion Criteria:

  • non-urogynecologic procedures, or conversion to open abdominal surgery will be excluded as additional or alternative sites of pain may contribute to possible confounding for the primary outcome of postoperative pain
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
164 participants (estimated)

Study arms

  • Active comparator
    Standard insufflation

    15 mmHg

    Procedure: Standard insufflation

  • Experimental
    Low Insufflation

    10 mm Hg

    Procedure: Low insufflation

Interventions

  • ProcedureStandard insufflation

    standard insufflation pressure of 15 mm Hg

  • ProcedureLow insufflation

    10 mm Hg of insufflation pressure

05

What researchers measure

Primary outcomes

  1. Postoperative Pain Visual Analog Scale

    Visual analog scale minimum 0 maximum 10 0 means no pain 10 means worst possible pain

    Time frame: 3 hours and 24 hours postop

Secondary outcomes

  1. Post-operative analgesia

    total dose of morphine milligram equivalents MME used during first days after surgery.

    Time frame: 0 - 3 days postoperative

  2. Surgeon visibility

    surgeon rating of intraoperative visibility on a Likert scale of 0 - 10. 0 means no visibility. 10 = optimum visibility.

    Time frame: immediately after surgery

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No — against local IRB

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07786337
Lead sponsor
University of Calgary
Responsible party
Shunaha Kim-Fine (Clinical Associate Professor, Head of Section of Urogynecology, University of Calgary) — Principal investigator
First posted
Aug 26, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Aug 26, 2026

Study contacts

Shunaha Kim-Fine, MD MS
Contact
skimfine@ucalgary.ca
403-944-1438
Louise Gofton
Contact
403-944-1438

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion